<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02235428</url>
  </required_header>
  <id_info>
    <org_study_id>244.2413</org_study_id>
    <nct_id>NCT02235428</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children</brief_title>
  <official_title>Double-blind, Controlled Trial to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, for 120 Minutes, in Acute Asthmatic Attacks in Young Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To determine whether addition of ipratropium bromide to salbutamol nebulisations produces
      significantly greater bronchodilation in young children presenting to an emergency department
      with an acute attack of asthma
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 1998</start_date>
  <primary_completion_date type="Actual">September 1998</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in pulmonary resistance (Rint) between T0 and T120</measure>
    <time_frame>Baseline, 120 minutes after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of accessory muscle recruitment on a 4-point scale</measure>
    <time_frame>Up to 120 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of wheezing on a 4-point scale</measure>
    <time_frame>Up to 120 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of dyspnoea on a 4-point scale</measure>
    <time_frame>Up to 120 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in respiratory rate</measure>
    <time_frame>Up to 120 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Oxygen Saturation (ambient air)</measure>
    <time_frame>Up to 120 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in measurement of pulmonary resistance</measure>
    <time_frame>Up to 120 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients dropped out because of lack of efficacy</measure>
    <time_frame>Up to 120 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 17 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients dropped out because of adverse events</measure>
    <time_frame>Up to 17 days after last drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinical significant findings in blood pressure</measure>
    <time_frame>Up to 120 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinical significant findings in heart rate</measure>
    <time_frame>Up to 120 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Admission rate</measure>
    <time_frame>120 minutes after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Patient Status by investigator on a 3-question list</measure>
    <time_frame>72 hours after drug admimistration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Ipratropium bromide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Salbutamol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium bromide</intervention_name>
    <arm_group_label>Ipratropium bromide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Salbutamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <arm_group_label>Ipratropium bromide</arm_group_label>
    <arm_group_label>Salbutamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Boys or girls between 3 and 6 years old

          -  Presenting to emergency departments with an acute asthmatic attack

          -  Requiring nebulised bronchodilator therapy

          -  Rint increased by 200 % compared to theoretical Rint

          -  Signed, informed consent obtained from the child's parents/legal guardian in
             accordance with current national legislation and good clinical practice (GCP) defined
             by the International Conference on Harmonization (ICH)

        Exclusion Criteria:

          -  Ipratropium bromide received within four hours before admission

          -  First acute asthmatic attack

          -  Hospital admission to intensive care with asthma within six months before inclusion

          -  Hospital admission for asthma during the month prior to inclusion

          -  Corticosteroid-dependent asthma (oral corticosteroid therapy) or recently stopped
             corticosteroid therapy

          -  Concomitant cardiac disease

          -  Life threatening disease requiring immediate management; including: silent chest on
             auscultation, cyanosis, bradycardia less than 60 beats/min (bpm), confusion, coma

          -  Hypersensitivity to ipratropium bromide, salbutamol, or to any of their excipients

          -  Renal or hepatic insufficiency

          -  Poorly controlled diabetes

          -  Patients suffering from a disease considered to be severe by the investigator and
             which, in the opinion of the investigator, could interfere or invalidate the
             measurements performed in the trial

          -  Past history of lung surgery

          -  Major respiratory disease: pulmonary fibrosis, bronchiectasis, sarcoidosis,
             tuberculosis, respiratory disease due to AIDS, cystic fibrosis

          -  Patients unable to follow with protocol or correctly undergo the evaluations

          -  Patients who are taking part in another clinical trial during this trial or who have
             done so within the month before the trial

          -  Previous participation in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2014</study_first_submitted>
  <study_first_submitted_qc>September 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2014</study_first_posted>
  <last_update_submitted>September 9, 2014</last_update_submitted>
  <last_update_submitted_qc>September 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

